MY ACCOUNT | NEWSLETTER |

A predictive algorithm for the optimal daily dosage of thiamazole to control cats with hyperthyroidism.

Clinical evidence update from Journal of veterinary internal medicine


Clinical Context

Peer-reviewed veterinary literature continues to shape everyday decision-making for feline patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.

What the Study Evaluated

A study published in Journal of veterinary internal medicine in 2026 evaluated a predictive algorithm for the optimal daily dosage of thiamazole to control cats with hyperthyroidism..

Key Findings

Hyperthyroidism is the most common endocrinopathy in cats and is frequently managed using anti-thyroid medication. To develop and validate an algorithm to predict the optimal starting daily dose of thiamazole required to control hyperthyroidism in cats. One hundred eighty-eight client-owned cats with hyperthyroidism for algorithm development (2011-2021) and 45 hyperthyroid cats to validate the algorithm (2022-2024). Retrospective case-control study. Cats with hyperthyroidism controlled medically using thiamazole within a year since diagnosis were enrolled. Controlled dose of thiamazole was categorized into "≤5 mg" or ">5 mg." Binary logistic...

Why It Matters for Veterinary Professionals

For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for feline patients.

Practical Interpretation

The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.

Clinical Takeaway

Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.

Read the full article here.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Fox tapeworm, a zoonotic parasite, found in Pacific Northwest

Like0
Dislike0

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients

Like0
Dislike0

Hypersomatotropism without concurrent diabetes mellitus in cats 28 cases (2014-2024).

Like0
Dislike0

ACVIM-endorsed statement consensus statement and systematic review on guidelines for the diagnosis and treatment of chronic inflammatory enteropathy in dogs.

Like0
Dislike0

Long term safety and efficacy of a functionalized nanogel with endothelin-1 and bradykinin receptor antagonist peptides for treatment of osteoarthritis of the metacarpophalangeal and distal interphalangeal joints in horses a descriptive clinical pilot stu

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top